Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani. Dear Fellow Shareholders: Clearmind’s overarching mission since inception has been to promptly…

Source

Previous articleMYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
Next articleThe atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital